





*milestones*

AND NEW PATHS



# BIC INTERNATIONAL CONFERENCE ROME, ITALY | 15 - 17 SEPTEMBER 2017

ORGANIZED BY



Fondazione IRCCS  
Ca' Granda  
Ospedale Maggiore  
Policlinico

Sistema Socio Sanitario



Regione  
Lombardia



CENTRO EMOFILIA E TROMBOSI  
ANGELO BIANCHI BONOMI

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico

## SCIENTIFIC COMMITTEE

P.M. Mannucci • F. Peyvandi • A.B. Federici • N. Ciavarella

WITH THE PATRONAGE OF



## Conference venue:

### The Church Palace Hotel

Via Aurelia, 481 - 00165 Rome - Italy

## CME accreditation:

The event is accredited for Italian (Agenas) and European (UEMS-EACCME) Continuing Medical Education with **19 credits**.

▶ **European CME Provider:** SMC Media Srl

▶ **Italian CME Provider:** Euro Medical Service (ID #3765)

To claim your credits please read the instructions at [www.bic2017.org](http://www.bic2017.org)

## On-site Secretariat is open at:

▶ **Thursday, 14 Sept.** 18:00-20:00

▶ **Saturday, 16 Sept.** 8:30-19:00

▶ **Friday, 15 Sept.** 7:30-18:30

▶ **Sunday, 17 Sept.** 8:30-18:00

Staff may be available beyond these hours and dates for transfer coordination.



### ORGANIZING SECRETARIAT: **SMC Media srl**

Via Giovanale, 7 • Milan - Italy

Tel. +39 02.83419430/1 • Fax. +39 02.93663665

[congress@smc-media.com](mailto:congress@smc-media.com) • [www.smc-media.com](http://www.smc-media.com)



/BICinternationalconferencehemophilia

[www.bic2017.org](http://www.bic2017.org)



Download the  
**9th BIC app** today

...and start **tweeting**  
and **creating connections**  
with your colleagues!



App Store



Google play

“

*This international conference, that takes place every three years in Italy and has reached the ninth edition, is focused upon the clinical and translational research of a group of rare disorders of the hemostatic system: **hemophilia, von Willebrand disease, rare bleeding disorders** and the **thrombotic microangiopathies** (such as: thrombotic thrombocytopenic purpura and hemolytic uremic syndrome). The invited speakers, from Europe, North America and Asia are among **the best experts** of these disorders, which are rare but of great relevance and clinical complexity.*

*We wish to welcome clinical and basic science researchers to the 9th BIC International Conference in Rome and look forward to interacting with them throughout the whole 3-day period.*

”

***The Scientific Committee***

*P.M. Mannucci, F. Peyvandi, A.B. Federici, N. Ciavarella*





# SCIENTIFIC PROGRAMME

## ▶▶▶ FRIDAY, 15th September

08.20 **Welcome speech**

*Pier Mannuccio Mannucci, Flora Peyvandi, Augusto B. Federici, Nicola Ciavarella*

### SCIENTIFIC SESSION 1: **Hemophilia**

**Chairs:** *Nicola Ciavarella (Italy), David Lillicrap (Canada)*

08.30 **Will severe hemophilia become more common in the future?**

**The effects of population demographics on the prevalence of hemophilia**  
*Manuel Carcao (Canada)*

09.00 **Determinants of factor VIII inhibitor risk. Is von Willebrand factor a key factor?**

*David Lillicrap (Canada)*

09.30 **Endocytosis of factor VIII by antigen-presenting cells:  
roles of von Willebrand factor and complement**

*Sébastien Lacroix-Desmazes (France)*

10.00 **Paradigm shift of the treatment of hemophilia A  
by factor VIII mimicking bispecific antibody**

*Midori Shima (Japan)*

10.30 **The challenges of innovative therapeutic interventions in hemophilia**

*Louis M. Aledort (USA)*

11.00 **Break & Poster Session** (*see ePoster Programme for details*)

### SCIENTIFIC SESSION 2: **Von Willebrand disease**

**Chairs:** *Giancarlo Castaman, Augusto B. Federici (Italy)*

11.30 **Von Willebrand factor regulation of blood vessel formation and function**

*Anna Maria Randi (UK)*

12.00 **Gastrointestinal bleeding in von Willebrand disease: an unresolved problem**

*Giancarlo Castaman (Italy)*

12.30 **The potential use of nanobodies in the treatment of von Willebrand disease  
and hemophilia**

*Peter Lenting (France)*

13.00 **Lunch & Poster Session** (*see ePoster Programme for details*)

## ORAL COMMUNICATIONS

14.30

### **Desmopressin (DDAVP): 40 years after**

*Chairs: Massimo Franchini, Pier Mannuccio Mannucci (Italy)*

- ▶ **Pharmacokinetic modelling to predict FVIII:C response to desmopressin and its reproducibility in non-severe hemophilia A patients**  
*Lisette Schütte (the Netherlands)*
- ▶ **Perioperative management of von Willebrand patients with desmopressin; Towards a predictive population PK model**  
*Jessica Heijdra (the Netherlands)*
- ▶ **The effect of F8 missense mutations on individual pharmacokinetic parameters of DDAVP response in nonsevere hemophilia A**  
*Janneke Loomans (the Netherlands)*
- ▶ **The intracellular binding of FVIII to VWF may allow a clinically useful response to DDAVP in patients with hemophilia A due to FVIII mutations impairing FVIII binding to VWF**  
*Marc Jacquemin (Belgium)*
- ▶ **Desmopressin in moderate hemophilia A patients: a treatment worth considering**  
*Janneke Loomans (the Netherlands)*
- ▶ **Safety and effectiveness of desmopressin for the management of bleeds, delivery and major surgery in mild-moderate von Willebrand disease: Results of the Pro-Des-Wil study in a cohort of 84 patients**  
*Augusto Federici (Italy)*

## SATELLITE SYMPOSIUM

15.30

### **Satellite Symposium** (not accredited for CME) Sponsored by Sobi

*Chairs: Stefan Lethagen, Stephen James*

#### **Beyond half-life extension: characterising how rFVIII-Fc impacts the immune system**

- ▶ **Welcome and Introduction**  
*Stefan Lethagen, Sobi™ (Sweden)*
- ▶ **Retrospective Real World Analysis of Haemophilia A Patients with Inhibitors Treated with rFVIII-Fc for Immune Tolerance Induction**  
*Jennifer Dumont, Bioverativ™ (USA)*
- ▶ **Elucidating rFVIII-Fc Interactions with the Immune System**  
*Katalin Kis-Toth, Bioverativ™ (USA)*
- ▶ **MHC Class II Presentation of Fc Tregitope and FVIII Epitopes in rFVIII-Fc: Potential Implications for Tolerance**  
*Margareta Wikén, Sobi™ (Sweden)*
- ▶ **Questions & Answers and Closing Remarks**  
*Stephen James, Sobi™ (Sweden)*

16.30

### **Break & Poster Session** (see ePoster Programme for details)

## SCIENTIFIC SESSION 3: **Thrombotic Microangiopathies**

*Chairs: Johanna Kremer Hovinga (Switzerland), Flora Peyvandi (Italy)*

17.00

### **Mechanism of thrombotic microangiopathy: lesson from zebrafish to men**

*X. Long Zheng (USA)*

17.30

### **Differential diagnosis of thrombotic microangiopathies**

*Jeffrey C. Laurence (USA)*

18.00

### **Immune repertoire in acquired TTP**

*Johanna Kremer Hovinga (Switzerland)*

## ▶▶▶ SATURDAY, 16th September

### SCIENTIFIC SESSION 4: **Gene Therapies**

**Chairs:** Luigi Naldini, Flora Peyvandi (Italy)

- 09.00 **Addressing vector immunogenicity in the development of AAV-based gene therapies for bleeding disorders**  
*Federico Mingozzi (France)*
- 09.30 **Liver-directed lentiviral gene therapy of hemophilia**  
*Luigi Naldini (Italy)*
- 10.00 **An update on UCL/St Jude Haemophilia studies: successes and obstacles ahead**  
*Amit Nathwani (UK)*
- 10.30 **Gene therapy in hemophilia A**  
*Wing Yen Wong (USA)*
- 11.00 **Break & Poster Session** (see ePoster Programme for details)

### SCIENTIFIC SESSION 5: **Von Willebrand Factor**

**Chairs:** Pier Mannuccio Mannucci (Italy), Denisa Wagner (USA)

- 11.30 **Von Willebrand factor in ischemic stroke**  
*Simon de Meyer (France)*
- 12.00 **Interplay between von Willebrand factor, ADAMTS13 and NETs**  
*Denisa Wagner (USA)*

### SATELLITE SYMPOSIA / LECTURES

- 12.30 **Satellite Lecture** (not accredited for CME) Sponsored by Roche  
*Chair: David Lillcrap (Canada)*  
**Haemophilia A: can we raise our treatment expectations?**  
*Elena Santagostino (Italy)*
- 13.00 **Lunch & Poster Session** (see ePoster Programme for details)
- 14.30 **Satellite Lecture** (not accredited for CME) Sponsored by Kedrion-LFB  
*Chair: Johannes B. Oldenburg (Germany)*  
**How to choose FVIII products in newly treated patients with severe hemophilia A: before and after SIPPET**  
*Pier Mannuccio Mannucci (Italy)*
- 15.00 **Satellite Symposium** (not accredited for CME) Sponsored by Shire  
*Chair: Anna Randi (UK). Co-Chair: Alessandro Gringeri (Austria)*  
**Recombinant von Willebrand Factor:  
An Innovative Therapeutic Option for Difficult to Control Bleeds**
- ▶ **Welcome & Introduction**  
*Anna Randi (UK)*
  - ▶ **Challenges, solutions, and role of recombinant von Willebrand Factor in difficult to control bleeds**  
*Andreas Tiede (Germany)*
  - ▶ **Peri-operative management with recombinant von Willebrand Factor in patients with VWD**  
*Flora Peyvandi (Italy)*
  - ▶ **The use of recombinant von Willebrand Factor in a real world setting**  
*Diane Nugent (USA)*
  - ▶ **Questions & Answers**  
*Anna Randi, Andreas Tiede, Flora Peyvandi, Diane Nugent, Alessandro Gringeri*
  - ▶ **Closing Remarks**  
*Alessandro Gringeri (Austria)*
- 16.00 **Break & Poster Session** (see ePoster Programme for details)

## SCIENTIFIC SESSION 6: **Von Willebrand factor and disease**

**Chairs:** Robert Montgomery, Zaverio M. Ruggeri (USA)

- 16.30 **Old concepts and new functions of von Willebrand factor: 2017**  
*Zaverio M. Ruggeri (USA)*
- 17.00 **Von Willebrand factor regulation and role in disease**  
*José Lopez (USA)*
- 17.30 **Collagen and von Willebrand factor interactions and beyond**  
*Pamela Christopherson (USA)*
- 18.00 **The genetics of von Willebrand disease**  
*Ann Goodeve (UK)*
- 18.30 **The many faces of thrombocytopenia in von Willebrand disease type 2B**  
*Cécile Denis (France)*

## ▶▶▶ **SUNDAY, 17th September**

### SCIENTIFIC SESSION 7: **Side effects of replacement therapy**

**Chairs:** Giovanni Di Minno (Italy), Frits R. Rosendaal (the Netherlands)

- 09.00 **Randomisation or real world data?**  
*Frits R. Rosendaal (the Netherlands)*
- 09.30 **Current prophylaxis regimens are delaying but not preventing onset of joint arthropathy**  
*Johannes B. Oldenburg (Germany)*
- 10.00 **Predictors of outcome in immune tolerance induction (ITI): the Italian Registry**  
*Giovanni Di Minno (Italy)*
- 10.30 **Do we need to monitor for neurological adverse events in hemophilia?**  
*Michael Makris (UK)*
- 11.00 **Break & Poster Session** (see ePoster Programme for details)

### ORAL COMMUNICATIONS SESSION

- 11.30 **Oral communications: Translational Science**  
*Chairs: Sébastien Lacroix-Desmazes (France), Karen Vanhoorelbeke (Belgium)*
- ▶ **Towards a clinically relevant hybrid adenovirus-Sleeping Beauty transposon vector for gene therapy for von Willebrand disease**  
*Irina Portier (Belgium)*
  - ▶ **Treatment of hemophilia A by injection of FVIII-encoding mRNA**  
*Jules Russick (France)*
  - ▶ **Application of combined gene and cell therapy within an implantable therapeutic device for the treatment of severe haemophilia A**  
*Chiara Borsotti (Italy)*
  - ▶ **Pharmacokinetic profile of rFVIII<sub>FC</sub>-VWF-XTEN (BIVV001) protein in cynomolgus monkey generated from a large-scale manufacturing stable cell line**  
*Joe Salas (USA)*
  - ▶ **Recombinant factor VIII Fc fusion protein exhibits immunomodulatory effects on antigen presenting cells**  
*Katalin Kis-Toth (USA)*
  - ▶ **Scavenger-receptor stabilin-2 is a major regulator of mouse VWF propeptide clearance**  
*Orla Rawley (Canada)*

- ▶ **An open conformation of ADAMTS13 is a hallmark of acute acquired thrombotic thrombocytopenic purpura**  
*Elien Roose (Belgium)*
- ▶ **Profiling of anti-ADAMTS13 antibodies derived from patients with acquired thrombotic thrombocytopenic purpura**  
*Nuno Graca (the Netherlands)*
- ▶ **The role of von Willebrand factor in experimental malaria-associated acute respiratory distress syndrome**  
*Sirima Kraisin (Belgium)*

13.00 | **Lunch & Poster Session** (see ePoster Programme for details)

14.00 | **Oral communications: Clinical Science**

*Chairs: Jenny Goudemand (France), Reinhard Schneppenheim (Germany)*

- ▶ **Fitusiran, an investigational RNAi therapeutic targeting antithrombin for the treatment of hemophilia A or B with and without inhibitors: Interim results from a Phase 2 extension study**  
*Pratima Chowdary (UK)*
- ▶ **“FEIBA Global Outcome study (FEIBA GO)” first data read-out: Real world bleeding frequency in inhibitors patients on prophylaxis with APCC**  
*Roberto Crea (Austria)*
- ▶ **A cumulative review on four decades of thrombo-embolic events reported with the use of activated prothrombin complex concentrate (APCC) in congenital hemophilia**  
*Alessandro Gringeri (Austria)*
- ▶ **Influence of variant VWF multimer patterns on the diagnosis of VWD type 2B**  
*Reinhard Schneppenheim (Germany)*
- ▶ **Comparing platelet-dependent von Willebrand factor activity assays in 661 patients with von Willebrand disease - from the WiN Study**  
*Johan Boender (the Netherlands)*
- ▶ **Is type 3 VWD an homogeneous group?**  
*Jenny Goudemand (France)*

## SCIENTIFIC SESSION 8: **Thrombotic thrombocytopenic purpura**

*Chairs: Dominique Meyer (France), Flora Peyvandi (Italy)*

15.00 | **Emerging concepts in acquired thrombotic thrombocytopenic purpura**

*Karen Vanhoorelbeke (Belgium)*

15.30 | **Immune recognition of ADAMTS13 in acquired thrombotic thrombocytopenic purpura (TTP)**

*Jan Voorberg (the Netherlands)*

16.00 | **Thrombotic microangiopathies**

*Paul Coppo (France)*

16.30 | **Break & Poster Session** (see ePoster Programme for details)

## SCIENTIFIC SESSION 9: **Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome**

*Chairs: Pier Mannuccio Mannucci, Giuseppe Remuzzi (Italy)*

17.00 | **The most recent advances in atypical hemolytic uremic syndrome (aHUS) and thrombotic thrombocytopenic purpura (TTP) including complement and von Willebrand factor (VWF) complement interactions**

*Marina Noris, Giuseppe Remuzzi (Italy)*

17.30 | **Treatment monitoring in the atypical hemolytic uremic syndrome (HUS)**

*Massimo Cugno (Italy)*





# ePOSTER PROGRAMME

ARCH OF CONSTANTINE

VITTORIA BRIDGE

## ▶▶▶ FRIDAY, 15th September

11.00 **Bleeding phenotype and target joints predict patients with zero bleeds given once-weekly prophylaxis with BAY 94-9027**

*E. Musi (Switzerland)*

11.15 **Comparing the one-stage and chromogenic assay: factor VIII activity assay discrepancy at baseline does not reflect assay discrepancy after desmopressin in non-severe hemophilia A patients**

*L. Schutte (the Netherlands)*

13.00 **BAY 1093884 target the Kunitz Domains 1 and 2 of TFPI and Blocks Its Function**

*P. Mathew (USA)*

13.15 **Nonacog beta pegol in adult and paediatric patients: pooled data from the paradigm™ clinical programme**

*M. Lapecorella (Italy)*

13.30 **Preliminary enrolment data from the U.S. post-marketing safety (PMS) study of rpFVIII in patients with acquired hemophilia**

*R. Crea (Austria)*

14.00 **Nonacog beta pegol for the prophylactic treatment of children with hemophilia B: interim results from the paradigm™5 clinical trial**

*M. Lapecorella (Italy)*

14.15 *POSSIBLE REPEAT TIME*

**Evaluation of a fully-automated chemiluminescent immunoassay for the rapid quantification of ADAMTS13 activity and the detection of ADAMTS13 inhibitors**

*M. Mirabet (Spain)*

**Immunoglobulin G subclass distribution of anti-ADAMTS13 antibodies and its association with HLA-DR-DQ haplotypes and clinical course in acquired thrombotic thrombocytopenic purpura**

*G. Sinkovits (Hungary)*

**Congenital (hereditary) thrombotic thrombocytopenic purpura (cTTP [hTTP], Upshaw-Schulman Syndrome): Patient experience, conceptual framework, and patient-reported outcome (PRO) instrument development**

*B. Ewenstein (USA)*

**Unraveling anti-spacer immunoprofiles of acquired TTP patients using anti-idiotypic antibodies**

*A. S. Schelpe (Belgium)*

**Prevention of relapses in patients affected by acquired TTP undergoing elective surgery**

*B. Ferrari (Italy)*

*POSSIBLE REPEAT TIME*

*POSSIBLE REPEAT TIME*



ARCH OF CONSTANTINE



VITTORIA BRIDGE

16.30 **Clustered *F8* missense mutations cause hemophilia A phenotypic heterogeneity by combination of altered splicing, protein secretion and activity**

*M. Pinotti (Italy)*

16.45 **Von Willebrand factor levels in patients with hemophilia**

*A. M. Milos (Croatia)*

**Diagnosis of Upshaw-Schulman syndrome in adulthood**

*B. Ferrari (Italy)*

**Modeling-guided identification of structural determinants contributing to conformational changes within ADAMTS13**

*B. Ercig (the Netherlands)*

## ▶▶▶ SATURDAY, 16th September

11.00 **Whole exome sequencing as a first tier test in diagnosing primary bleeding disorders: WES First**

*Y. Smit (the Netherlands)*

**Quantitative ELISA assay for in vivo proteolysis of von Willebrand factor and bleeding: A pilot study in type 2A(IIA) von Willebrand disease**

*S. Susen (France)*

11.15 **The rare coagulation factor deficiencies: Single centre experience**

*F. D. Koseoglu (Turkey)*

**Development of a gene therapy strategy for von Willebrand disease based on dual adeno-associated virus vectors**

*E. Barbon (France)*

13.00 *POSSIBLE REPEAT TIME*

**Efficacy, safety, and presurgical pharmacokinetics of recombinant VWF (rVWF) in patients with severe VWD who are undergoing elective surgical procedures**

*F. Peyvandi (Italy)*

13.15 **Effectiveness and safety of rFVIIa in paediatric Glanzmann Thrombasthenia patients: data from the international Glanzmann Thrombasthenia Registry**

*A. Roveda (Italy)*

**Laboratory diagnosis of von Willebrand disease type 2A versus LVAD-induced acquired von Willebrand syndrome**

*S. Deconinck (Belgium)*

13.30 **Rare bleeding disorders In the Netherlands**

*J. Saes (the Netherlands)*

**Differential diagnosis between type 2A and 2B VWD in a 2-years old female child with a *de novo* novel mutation**

*M. T. Pagliari (Italy)*

14.00 **Simultaneous measurement of thrombin and plasmin generation in patients with Factor XI deficiency**

*J. Saes (the Netherlands)*

**Platelet function analyzer measurement of closure time as a biomarker for activity of high and ultralarge multimers of recombinant von Willebrand factor (rVWF)**

*P. Turecek (Austria)*

14.15 | POSSIBLE REPEAT TIME

| POSSIBLE REPEAT TIME

16.00 | **Acquired factor V inhibition due to Bactrim therapy – A previously unreported cause of a rare coagulopathy**  
*R. Gately (Australia)*

| **Usefulness of von Willebrand factor propeptide in the differential diagnosis between von Willebrand disease and acquired von Willebrand syndrome**  
*F. Stufano (Italy)*

16.15 | **Hepatitis C viral infection in patients with hemophilia; An experience of Ege Adult Haemophilia Center**  
*F. D. Koseoglu (Turkey)*

| **Recombinant human von Willebrand factor has a unique pattern of ultra large multimers: results from physico-, biochemical and *in vivo* studies**  
*P. Turecek (Austria)*

## ▶▶▶ SUNDAY, 17th September

11.00 | **Development of inhibitors in PUPs: Different scenario, same outcome**  
*S. Trakymiene (Lithuania)*

| **Soluble glycoprotein VI (sGPVI) measurement is a useful biomarker of platelet activation in heparin-induced thrombocytopenia (HIT) and correlates with thrombotic events.**  
*C. W. Tan (Australia)*

11.15 | **A novel macrophage-mediated pathway regulates enhanced clearance of hyposialylated von Willebrand factor *in vivo***  
*J. O'Sullivan (Ireland)*

| **Child-onset thrombotic thrombocytopenic purpura: the French Reference Center for Thrombotic MicroAngiopathies experience**  
*B. Joly (France)*

13.00 | **Stabilin-2 deficiency increases pro-coagulant activity and deep vein thrombosis in mice**  
*A. Michels (Canada)*

| **Life-threatening pregnancy-associated atypical haemolytic uraemic syndrome and its response to eculizumab**  
*R. Gately (Australia)*

13.15 | **Enhanced local disorder in a clinically elusive von Willebrand factor provokes high-affinity platelet clumping**  
*M. Auton (USA)*

| POSSIBLE REPEAT TIME

13.30 | **A cell-based assay to quantify von Willebrand factor mutant binding to integrin  $\alpha IIb\beta 3$**   
*M. A. Brehm (Germany)*

| POSSIBLE REPEAT TIME

14.00 | **Variability in blood outgrowth endothelial cell characteristics and related von Willebrand factor parameters**  
*A. De Jong (the Netherlands)*

| POSSIBLE REPEAT TIME

16.30 | POSSIBLE REPEAT TIME

| POSSIBLE REPEAT TIME

16.45 | POSSIBLE REPEAT TIME

| POSSIBLE REPEAT TIME



# FACULTY

## L. M. Aledort



USA

Professor of Medicine, Hematology and Medical Oncology - Icahn Mount Sinai School of Medicine - New York, USA.

## M. Carcao



CANADA

Associate Professor - Hospital for Sick Children, Hemophilia Clinic, Toronto (ON), Canada.

## G. Castaman



ITALY

Director of Center for Bleeding Disorders and Coagulation, Department of Oncology, Careggi University Hospital, Florence, Italy.

## P. Christopherson



USA

Blood Research Institute, BloodCenter of Wisconsin, Milwaukee, USA.

## P. Coppo



FRANCE

French Reference Center for Thrombotic Microangiopathies; Professor of Haematology at Saint-Antoine Hospital, Paris, France.

## M. Cugno



ITALY

Department of medical, surgical and transplant physiopathology of the University of Milan, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, University of Milan, Milan, Italy.

## S. De Meyer



BELGIUM

Associate Professor at the Laboratory for Thrombosis Research, KU Leuven Kulak, Kortrijk, Belgium.

## C. Denis



FRANCE

Institut National de la Santé et de la Recherche Médicale (INSERM) U1176, Le Kremlin-Bicetre, France.

## G. Di Minno



ITALY

Department of Clinical and Experimental Medicine, University of Naples Federico II, Naples, Italy.

## M. Franchini



ITALY

Servizio di immunoematologia e trasfusione, Azienda Ospedaliera Carlo Poma, Mantova, Italy.

## A. C. Goodeve



UK

Head of Sheffield Haemostasis Research Group - Department of Infection, Immunity & Cardiovascular Disease - Faculty of Medicine, Dentistry and Health - University of Sheffield, Sheffield, UK.

## J. A. Kremer Hovinga



SWITZERLAND

Head of the Hemostasis Research Laboratory at Berne University Hospital, Bern, Switzerland.

## S. Lacroix-Desmazes



FRANCE

Institut National de la Santé et de la Recherche Médicale (INSERM), UMRS 1138, Centre de Recherche des Cordeliers Paris, France.

## J. C. Laurence



USA

Professor of Medicine, Weill Cornell Medical College, and Attending Physician, New York Presbyterian Hospital-Cornell, New York, USA.

## P. J. Lenting



FRANCE

Inserm U770, Le Kremlin-Bicêtre, France.

## D. Lillicrap



CANADA

Department of Pathology and Molecular Medicine, Richardson Laboratory, Queen's University, Kingston (ON), Canada.

## J. A. López



Bloodworks Northwest Research Institute –  
Professor of Medicine, Division of Hematology  
– University of Washington – School of  
Medicine, Seattle, USA.

## M. Makris



Professor of Haemostasis and Thrombosis  
at University of Sheffield and Director of the  
Sheffield Haemophilia and Thrombosis Centre,  
Sheffield, UK.

## D. Meyer



Professeur émérite d'hématologie, Université  
Paris XI, Académie des sciences, Paris, France.

## F. Mingozzi



Associate Professor, University Pierre and  
Marie Curie, Paris, Team Leader, Genethon,  
Evry, France.

## R. R. Montgomery



Pediatric hematologist at the Blood Research  
Institute in Milwaukee, USA.

## L. Naldini



Director of the San Raffaele Telethon Institute  
for Gene Therapy and Professor at the San  
Raffaele University, Milan, Italy.

## A. Nathwani



Research Department of Haematology, Cancer  
Institute, Faculty of Medical Sciences, London,  
UK.

## M. Noris



Laboratory of Immunology and Genetics of  
Rare Diseases – IRCCS-Mario Negri Institute for  
Pharmacological Research – Ranica (BG), Italy.

## J. Oldenburg



Chairman and Director of the University Clinic  
Bonn Institute of Experimental Haematology  
and Transfusion Medicine, Bonn, Germany.

## A. M. Randi



Professor of Cardiovascular Medicine  
– Imperial Centre for Translational  
and Experimental Medicine – Imperial  
College London NHLI Vascular Sciences –  
Hammersmith Hospital – London, UK.

## G. Remuzzi



Professor of Nephrology, University of Milan,  
Italy, Mario Negri Institute for Pharmacological  
Research – Centro Anna Maria Astori – Science  
and Technology Park “Kilometro Rosso”,  
Bergamo, Italy.

## F. R. Rosendaal



Professor of Clinical Epidemiology, Leiden  
University Medical Center, Leiden, the  
Netherlands.

## Z. M. Ruggeri



Department of Molecular and Experimental  
Medicine, Scripps Clinic, La Jolla (CA), USA.

## M. Shima



Department of Pediatrics, Nara Medical  
University – Nara, Japan.

## K. Vanhoorelbeke



Faculty of Science, Campus Kulak Kortrijk, KU  
Leuven Kortrijk, Belgium.

## J. Voorberg



Department of Plasma Proteins – Sanquin  
Research and University of Amsterdam,  
Amsterdam, the Netherlands.

## D. Wagner



Edwin Cohn Professor of Pediatrics Center  
for Blood Research Professor of Pediatrics,  
Program in Cellular and Molecular Medicine  
and Div. of Hematology / Oncology. Boston  
Children's Hospital. Harvard Medical School,  
Boston, USA.

## W. Y. Wong



BioMarin, USA.

## X.L. Zheng



Robert B. Adams Endowed Professor and  
Director, Laboratory Medicine - Interim  
Director, Informatics - Department of  
Pathology UAB, the University of Alabama at  
Birmingham, AL, USA.

THURSDAY

14

The Church Palace Hotel

## Welcome dinner

Welcome Dinner will run continuously from 7.30 p.m. until late hours (approx. 11:00 p.m.) in order to welcome all incoming delegates to take in the first glimpse of the 9th BIC friendly atmosphere and a delicious bite. Come in as you arrive and enjoy.



FRIDAY

15

Cloister of Confraternita S. Giovanni Battista de' Genovesi

## Conference dinner + *Officinalia et aromatica* game

For centuries, merchants, pilgrims and men of culture have flocked to the Eternal City, finding accommodation in the city's monasteries, guesthouses and hospices. It is with this spirit that we offer the guests of the 9th BIC International Conference an unforgettable dinner in Trastevere, inside the cloister of a 15th-century hospice dedicated to the accommodation and care of travellers that was built by the Republic of Genoa to support its fellow citizens visiting Rome. In this cloister, you will be served a dinner featuring traditional Rome dishes, with each dish celebrating the simple raw ingredients that are cultivated in Rome and its surrounding areas and flavoured with the many traditional herbs that are native to the rich Mediterranean countryside. Just like in ancient times when hospices had on the premises a "pharmacy" of medicinal herbs, that evening we will recreate this ancient atmosphere and a botanist will explain to guests the different characteristics of the medicinal plants, native to the Mediterranean, and their use in both food and pharmacology.

- ▶ Bus pick up at 7.30 p.m. in the lobby of the Church Palace Hotel.



SUNDAY

17

On the beach!

## Arrivederci dinner

Informal seafood dinner on the beach, 20km away from the hotel on the Roman coast. The ideal setting for the last BIC team building competition, a **beach volley match**, and the **final BIC competition award ceremony**.

- ▶ Transfer provided from the Church Palace Hotel at 6.00 p.m.



▶ Reserve your dinners at the **Conference Secretariat**

# BIC INTERNATIONAL CONFERENCE

## ROME, ITALY | 15 - 17 SEPTEMBER 2017

WITH THE CONTRIBUTION OF

### MAJOR SPONSORS



### SPONSORS



Publisher • Event Planner • Multimedia Communication



PLEASE JOIN US AT THE SHIRE SPONSORED  
SYMPOSIUM TO LEARN MORE ABOUT:

**RECOMBINANT VON WILLEBRAND FACTOR:  
AN INNOVATIVE THERAPEUTIC OPTION FOR  
DIFFICULT TO CONTROL BLEEDS**

**Saturday 16th September 2017 | 15:00 – 16:00**

BIC International Conference 2017 | Room: Auditorium  
The Church Palace Hotel, Rome, Italy

**Chair:**

Anna Randi

**Co-Chair:**

Alessandro Gringeri

**Faculty:**

Andreas Tiede

Flora Peyvandi

Diane Nugent